Affiliation:
1. IĞDIR ÜNİVERSİTESİ, IĞDIR SAĞLIK HİZMETLERİ MESLEK YÜKSEKOKULU
2. HASAN KALYONCU ÜNİVERSİTESİ
Abstract
Aim: This study was conducted to investigate the risk of type 2 diabetes, behavioral and familial risk factors, and awareness of type 2 diabetes in students.
Method: The research was applied to students of a state university. In data collection, "informed consent form", "questions about social-demographic characteristics", "Finnish Type-2 DM Risk Scale (FINDRISK) and Type 2 diabetes awareness level, and questions about behavioral risk factors questionnaire" were used. Frequency and percentage calculation, independent groups t-test, and one-way ANOVA test were used in the analysis. Post-Hoc tests were used to determine the source of the difference in groups with a significant difference.
Results: It was determined that the average of the Findirisk scale of the students was 6.16±3.66 and the mean of the awareness level scale about Type 2 DM was 14.63±3.62. In addition, there is a weak negative correlation between the diabetes risk determined according to the Findrisk scale of the students and the level of knowledge of type 2 DM.(r=0.038, p>0.05).
Conclusion: It was observed that the risk of diabetes decreased as the awareness level of the students participating in the study increased.
Reference40 articles.
1. Olgun N, Çelik S. All aspects of internal medicine nursing book. Ankara Nobel Medical Bookstores. 2021:327-33.
2. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022;183:109119.
3. Ministry of Health TC. World Diabetes Day 2020. General Directorate of Health Promotion. 2020:https://sggm.saglik.gov.tr/TR-76887/dunya-diyabet-gunu-2020.html.
4. IDF DA. IDF Diabetes Atlas 10th edition. https://diabetesatlasorg/atlas/tenth-edition/. 2021( International Diabetes federation).
5. Salem A, Men P, Ramos M, Zhang Y-J, Ustyugova A, Lamotte M. Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research. 2021;10(6):469-80.